Annual Financials for EyePoint Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. |
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
Sales/Revenue
|
5.86M | 20.37M | 34.44M | 36.94M | 41.4M | |
Sales Growth |
- | 247.76% | 69.10% | 7.27% | 12.09% | |
Cost of Goods Sold (COGS) incl. D&A |
- | 5.15M | 8.28M | 10.64M | 10.38M | |
COGS excluding D&A |
- | 2.54M | 5.64M | 7.87M | 7.93M | |
Depreciation & Amortization Expense |
2.65M | 2.6M | 2.65M | 2.77M | 2.45M | |
Depreciation |
194,000 | 144,000 | 189,000 | 311,000 | 396,000 | |
Amortization of Intangibles |
2.46M | 2.46M | 2.46M | 2.46M | 2.05M | |
COGS Growth |
- | - | 60.95% | 28.40% | -2.45% | |
Gross Income |
- | 15.22M | 26.15M | 26.3M | 31.03M | |
Gross Income Growth |
- | - | 71.86% | 0.57% | 17.97% | |
Gross Profit Margin |
- | - | - | - | 74.94% | NA |
|
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
SG&A Expense |
52.32M | 63.08M | 63.44M | 81.58M | 109.97M | |
Research & Development |
20.82M | 15.37M | 17.42M | 28.5M | 49.64M | |
Other SG&A |
31.5M | 47.71M | 46.02M | 53.08M | 60.32M | |
SGA Growth |
- | 20.56% | 0.58% | 28.58% | 34.80% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
18.89M | 3.81M | 905,000 | (2.07M) | 22.26M | |
EBIT after Unusual Expense |
(68M) | (51.67M) | (38.2M) | (53.21M) | (101.2M) | |
Non Operating Income/Expense |
(18.89M) | - | - | - | - | |
Non-Operating Interest Income |
734,000 | 1.05M | 58,000 | 292,000 | 2.13M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
3.28M | 6.18M | 7.26M | 5.5M | 3.19M | |
Interest Expense Growth |
- | 88.06% | 17.50% | -24.24% | -42.00% | |
Gross Interest Expense |
3.28M | 6.18M | 7.26M | 5.5M | 3.19M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(89.44M) | (56.79M) | (45.39M) | (58.42M) | (102.25M) | |
Pretax Income Growth |
- | 36.50% | 20.07% | -28.69% | -75.04% | |
Pretax Margin |
- | - | - | - | -246.97% | NA |
Income Tax |
- | - | - | - | - | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(89.44M) | (56.79M) | (45.39M) | (58.42M) | (102.25M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(89.44M) | (56.79M) | (45.39M) | (58.42M) | (102.25M) | |
Net Income Growth |
- | 36.50% | 20.07% | -28.69% | -75.04% | |
Net Margin Growth |
- | - | - | - | -246.97% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(89.44M) | (56.79M) | (45.39M) | (58.42M) | (102.25M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(89.44M) | (56.79M) | (45.39M) | (58.42M) | (102.25M) | |
EPS (Basic) |
(10.50) | (5.44) | (3.54) | (2.03) | (2.74) | |
EPS (Basic) Growth |
- | 48.14% | 35.05% | 42.56% | -34.90% | |
Basic Shares Outstanding |
8.51M | 10.43M | 12.84M | 28.76M | 37.32M | |
EPS (Diluted) |
(10.50) | (5.44) | (3.54) | (2.03) | (2.74) | |
EPS (Diluted) Growth |
- | 48.14% | 35.05% | 42.56% | -34.90% | |
Diluted Shares Outstanding |
8.51M | 10.43M | 12.84M | 28.76M | 37.32M | |
EBITDA |
(46.47M) | (45.26M) | (34.64M) | (52.51M) | (76.49M) | |
EBITDA Growth |
- | 2.60% | 23.46% | -51.57% | -45.69% | |
EBITDA Margin |
- | - | - | - | -184.75% | NA |